Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

NCT04934774 is registered in ClinicalTrials.gov with iCell Gene Therapeutics as lead sponsor.

NCT NCT04934774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04934774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
Lead sponsor
iCell Gene Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
December 1, 2020
Completion date
June 1, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell acute lymphoblastic leukemia, t-cell acute lymphoblastic lymphoma, t-cell non-hodgkin lymphoma